India's Dr Lal Pathlabs falls on volume growth concerns

Dr. Lal PathLabs

22/02/2023 08:06

** Shares of Dr. Lal Pathlabs  DLPA.NS  fall as much as
3.06% to 1,922.10 rupees, a two-week low
    ** Diagnostic and healthcare services provider, in an
investor conference on Tuesday, says volume growth has been hurt
due to trial purchases by patients on competing platforms
    ** Adds Suburban Diagnostics, which DLPA acquired in 2021,
faced challenges on the back of fall in COVID-19 cases, even as
costs remained high 
    ** Says Suburban and DLPA will be further integrated
    ** Of the 20 analysts tracking DLPA, five suggest "buy", 11
recommend "sell" and four maintain "hold"; median PT is 2,005
rupees
 (Reporting by Bharath Rajeswaran in Bengaluru)
 ((bharath.rajeswaran@thomsonreuters.com; Mobile:
+919769003463))